|Day Low/High||58.54 / 59.40|
|52 Wk Low/High||56.32 / 77.12|
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.
Investors need to read the Real Money commentary regarding Bristol Myers to get a true read on the stock, said TheStreet's Jim Cramer.
Don't be surprised; we view Bristol-Myers as "down, not out."
BMY dropped after the bad news about a recent failed clinical trial of a new drug. But now the signs are there for a bullish reversal.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
Jim Cramer ponders how the playing field is being leveled and how three stocks indicate a change in interest rates.
Johnson & Johnson, American Electric Power and Federal Realty say rates are going higher.
Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.
Bernstein analysts say the impact of Bristol-Myers Squibb's (BMY) failed cancer drug trial will be "greater than many investors expect."
Jim Cramer ponders how retail is faring, and how the Valeant probe harkens back to a prior time.
Bristol-Myers' (BMY) stock rating was cut to 'hold' from 'buy' at Berenberg on Thursday.
The government's investigation into Valeant sn't a reason to sell the stock, but there are plenty of other reasons not to own it, according to Jim Cramer.
Don't sell the stock just because of the reported federal investigation, Cramer says.
Go ahead and sell Valeant on the news, if you want. But history has a different lesson.
BMY is unlikely to stay in the low $60s for long.
Wise investors should not follow analysts who have downgraded Bristol Myers Squibb, but should instead purchase the stock on sale.
Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.
The failed trial is among the biggest single blows by a major pharma player.
Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.
Energy, financial and technology stocks dominate names showing potential for higher prices.
We should be hearing more bad news from the banks but we're not. Cramer wants to know why.
U.S. stocks pulled lower as a selloff in health care soured the jobs-inspired rally that pushed benchmark indices to record highs last week.
Credit Suisse downgraded Bristol-Myers Squibb to NEUTRAL from OUTPERFORM and lowered its price target to $63 from $86 following the latest announcement on Opdivo.
Jim Cramer says the markets don't understand Bristol-Myers Squibb and Allergan.